Local adverse effects associated with the use of inhaled corticosteroids in patients with moderate or severe asthma;Eventos adversos locais associados ao uso de corticosteroides inalatórios em pacientes com asma moderada ou grave

Jornal Brasileiro de Pneumologia

Volumn 39, Issue 4, 2013, Pages 409-417

  Pinto, Charleston Ribeiro ^a   Almeida, Natalie Rios ^b   Marques, Thamy Santana ^c   Yamamura, Laira Lorena Lima ^d   Costa, Lindemberg Assunção ^e   Souza Machado, Adelmir ^e  

^a UNIVERSIDADE ESTADUAL DO SUDOESTE DA BAHIA   (Brazil)

^b ESCOLA BAHIANA DE MEDICINA E SAÚDE PÚBLICA   (Brazil)

^c General Hospital Roberto Santos   (Brazil)

^d Bahia State Health Department   (Brazil)

^e FEDERAL UNIVERSITY OF BAHIA   (Brazil)

Author keywords

Administration; Asthma; Glucocorticoids; Inhalation; Pharmaceutical services

Indexed keywords

ANTIASTHMATIC AGENT; BECLOMETASONE; BUDESONIDE; GLUCOCORTICOID;

ARTICLE; ASTHMA; CHEMICALLY INDUCED DISORDER; CROSS-SECTIONAL STUDY; DRUG EFFECT; FEMALE; HOARSENESS; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; OROPHARYNX; SEVERITY OF ILLNESS INDEX; THIRST;

ADMINISTRATION, INHALATION; ANTI-ASTHMATIC AGENTS; ASTHMA; BECLOMETHASONE; BUDESONIDE; CROSS-SECTIONAL STUDIES; FEMALE; GLUCOCORTICOIDS; HOARSENESS; HUMANS; MALE; MIDDLE AGED; OROPHARYNX; SEVERITY OF ILLNESS INDEX; THIRST;

EID: 84884793127     PISSN: 18063713     EISSN: 18063756     Source Type: Journal    
DOI: 10.1590/S1806-37132013000400003     Document Type: Article

References (24)

1. Global Initiative for Asthma [homepage on the Internet]. Bethesda: Global Initiative for Asthma. [cited 2013 Feb 08]. Global Strategy for Asthma Management and Prevention 2012. [Adobe Acrobat document, 128p.]. Available from: http://www.ginasthma.org/local/uploads/files/GINA_Report_March13.pdf
2. Sociedade Brasileira de Pneumologia e Tisiologia. Diretrizes da Sociedade Brasileira de Pneumologia e Tisiologia para o Manejo da Asma 2012. J Bras Pneumol. 2012;38(Suppl 1):S1-S46.
3. Buhl R. Local oropharyngeal side effects of inhaled corticosteroids in patients with asthma. Allergy. 2006;61(5):518-526. http://dx.doi.org/10.1111/j.1398-9995.2006.01090.x PMid:16629778
4. Hanania NA, Chapman KR, Kesten S. Adverse effects of inhaled corticosteroids. Am J Med. 1995;98(2):196-208. http://dx.doi.org/10.1016/S0002-9343(99)80404-5
5. Roland NJ, Bhalla RK, Earis J. The local side effects of inhaled corticosteroids: current understanding and review of the literature. Chest. 2004; 126(1):213-219. http://dx.doi.org/10.1378/chest.126.1.213 PMid:15249465
6. Foster JM, van Sonderen E, Lee AJ, Sanderman R, Dijktra A, Postma DS, et al. A self-rating scale for patient-perceived side effects of inhaled corticosteroids. Respir Res. 2006;7:131. http://dx.doi.org/10.1186/1465-9921-7-131 PMid:17062139 PMCid:1637103
7. Foster JM, Aucott L, Van der Werf RH, van der Meijden MJ, Schraa G, Postma DS, et al. Higher patient perceived side effects related to higher daily doses of inhaled corticosteroids in the community: a cross-sectional analysis. Respir Med. 2006;100(8):1318-1336. http:// dx.doi.org/10.1016/j.rmed.2005.11.029 PMid:16442275
8. Bhalla RK, Jones AS, Roland NJ. Prevalence of pharyngeal and laryngeal complications in adult asthmatics using inhaled corticosteroids. J Laryngol Otol. 2008;122(10):1078-1083. http://dx.doi.org/10.1017/S0022215107001272 PMid:18201390
9. Dubus JC, Marguet C, Deschildre A, Mely L, Le Roux P, Brouard J, et al. Local side-effects of inhaled corticosteroids in asthmatic children: influence of drug, dose, age, and device. Allergy. 2001;56(10):944-948. http://dx.doi. org/10.1034/j.1398-9995.2001.00100.x PMid:11576072
10. Ivanova JI, Birnbaum HG, Hsieh M, Yu AP, Seal B, van der Molen T, et al. Adherence to inhaled corticosteroid use and local adverse events in persistent asthma. Am J Manag Care. 2008;14(12):801-809. PMid:19067497
11. Molimard M, Le Gros V, Robinson P, Bourdeix I. Prevalence and associated factors of oropharyngeal side effects in users of inhaled corticosteroids in a real-life setting. J Aerosol Med Pulm Drug Deliv. 2010;23(2):91-5. http://dx.doi.org/10.1089/jamp.2009.0762 PMid:19778267
12. Fitzgerald JM, Chan CK, Holroyde MC, Boulet LP. The CASE survey: patient and physician perceptions regarding asthma medication use and associated oropharyngeal symptoms. Can Respir J. 2008;15(1):27-32. PMid:18292850 PMCid:2677852
13. Boulet LP. Perception of the role and potential side effects of inhaled corticosteroids among asthmatic patients. Chest. 1998;113(3):587-592. http://dx.doi.org/10.1378/chest.113.3.587 PMid:9515829
14. Foster JM, van der Molen T, Jong-Van de dan Berg L. Patient-reporting of side effects may provide an important source of information in clinical practice. Eur J Clin Pharmacol. 2007;63(10):979-980; author reply 981. http://dx.doi.org/10.1007/s00228-007-0339-8 PMid:17618426 PMCid:2039823
15. Williamson IJ, Matusiewicz SP, Brown PH, Greening AP, Crompton GK. Frequency of voice problems and cough in patients using pressurized aerosol inhaled steroid preparations. Eur Respir J. 1995;8(4):590-592. PMid:7664859
16. Ihre E, Zetterström O, Ihre E, Hammarberg B. Voice problems as side effects of inhaled corticosteroids in asthma patients--a prevalence study. J Voice. 2004;18(3):403-414. http://dx.doi.org/10.1016/j. jvoice.2003.05.003 PMid:15331115
17. Korsgaard J, Ledet M. Potential side effects in patients treated with inhaled corticosteroids and long-acting beta2-agonists. Respir Med. 2009;103(4):566-573. http://dx.doi.org/10.1016/j.rmed.2008.10.028 PMid:19136239
18. Gallivan GJ, Gallivan KH, Gallivan HK. Inhaled corticosteroids: hazardous effects on voice-an update. J Voice. 2007;21(1):101-111. http://dx.doi.org/10.1016/j. jvoice.2005.09.003 PMid:16442776
19. Williams AJ, Baghat MS, Stableforth DE, Cayton RM, Shenoi PM, Skinner C. Dysphonia caused by inhaled steroids: recognition of a characteristic laryngeal abnormality. Thorax. 1983;38(11):813-821. http://dx.doi.org/10.1136/thx.38.11.813 PMid:6648863 PMCid:459669
20. Lorimer S, Cox A, Langford NJ. A patient's perspective: the impact of adverse drug reactions on patients and their views on reporting. J Clin Pharm Ther. 2012;37(2):148-152. http://dx.doi.org/10.1111/j.1365-2710.2011.01258.x PMid:21592157
21. Medawar C, Herxheimer A, Bell A, Jofre S. Paroxetine, panorama and user reporting of ADRs: consumer intelligence matters in clinical practice and post-marketing surveillance. Int J Risk Saf Med. 2002;15:161-169.
22. Britten N, Stevenson F, Gafaranga J, Barry C, Bradley C. The expression of aversion to medicines in general practice consultations. Soc Sci Med. 2004;59(7):1495-1503. http://dx.doi.org/10.1016/j.socscimed.2004.01.019 PMid:15246177
23. Lamb GC, Green SS, Heron J. Can physicians warn patients of potential side effects without fear of causing those side effects? Arch Intern Med. 1994;154(23):2753-2756. http://dx.doi.org/10.1001/archinte.1994.00420230150018 PMid:7993161 24.
24. Organização Pan-Americana da Saúde Brasil [homepage on the Internet]. Brasília: Organização Pan-Americana da Saúde Brasil. [cited 2012 Oct 20]. A importância da Farmacovigilância. Available from: http://new.paho.org/bra/index.php?option=com_docman&task=doc_details&gid=745&Itemid=423